Trevanne Matthews Hew Lara Zuberi
10.1177/2324709619864989
J Investig Med High Impact Case Rep
2019 Jan-Dec;7:2324709619864989.
brca1 parp inhibitor breast cancer gout olaparib triple-negative breast cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/31375040/
Antineoplastic Agents / therapeutic use Carcinoma, Papillary / drug therapy Gout / chemically induced Liver Neoplasms / secondary Phthalazines / therapeutic use Piperazines / therapeutic use Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use Triple Negative Breast Neoplasms / drug therapy Ubiquitin-Protein Ligases / genetics
Antineoplastic Agents / therapeutic use Carcinoma, Papillary / drug therapy Gout / chemically induced Liver Neoplasms / secondary Phthalazines / therapeutic use Piperazines / therapeutic use Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use Triple Negative Breast Neoplasms / drug therapy Ubiquitin-Protein Ligases / genetics Case Reports Antineoplastic Agents / adverse effects Carcinoma, Papillary / genetics Carcinoma, Papillary / pathology Female Humans Liver Neoplasms / drug therapy Middle Aged Phthalazines / adverse effects Piperazines / adverse effects Poly(ADP-ribose) Polymerase Inhibitors / adverse effects Treatment Outcome Triple Negative Breast Neoplasms / genetics Triple Negative Breast Neoplasms / pathology Antineoplastic Agents Phthalazines Piperazines Poly(ADP-ribose) Polymerase Inhibitors BRAP protein, human Ubiquitin-Protein Ligases olaparib
PMC6681253
31375040
PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms
2019